Provided by Tiger Fintech (Singapore) Pte. Ltd.

Achilles Therapeutics plc

1.48
0.0000
Volume:- -
Turnover:- -
Market Cap:63.03M
PE:-0.89
High:1.48
Open:1.48
Low:1.48
Close:1.48
52wk High:1.51
52wk Low:0.9220
Shares:42.59M
Float Shares:20.85M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6590
EPS(LYR):-1.7428
ROE:-52.12%
ROA:-30.17%
PB:0.61
PE(LYR):-0.85

Loading ...

Company Profile

Company Name:
Achilles Therapeutics plc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.